Charles River Laboratories Intl. (CRL) Rating Lowered to C+ at TheStreet

Charles River Laboratories Intl. (NYSE:CRL) was downgraded by stock analysts at TheStreet from an “a-” rating to a “c+” rating in a research report issued on Tuesday.

CRL has been the subject of a number of other reports. Robert W. Baird set a $117.00 target price on shares of Charles River Laboratories Intl. and gave the company a “buy” rating in a report on Monday, November 13th. Zacks Investment Research raised shares of Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and set a $129.00 target price for the company in a report on Tuesday, October 24th. Evercore ISI assumed coverage on shares of Charles River Laboratories Intl. in a report on Thursday, January 18th. They issued an “in-line” rating and a $117.00 target price for the company. SunTrust Banks lowered shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating and raised their target price for the company from $107.89 to $111.00 in a report on Monday, January 22nd. They noted that the move was a valuation call. Finally, Bank of America cut their target price on shares of Charles River Laboratories Intl. from $117.00 to $115.00 and set a “buy” rating for the company in a report on Friday, November 10th. Seven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Charles River Laboratories Intl. presently has a consensus rating of “Buy” and a consensus target price of $114.85.

Shares of Charles River Laboratories Intl. (NYSE CRL) opened at $110.31 on Tuesday. The company has a current ratio of 1.78, a quick ratio of 1.62 and a debt-to-equity ratio of 1.06. Charles River Laboratories Intl. has a fifty-two week low of $86.25 and a fifty-two week high of $119.05. The stock has a market cap of $5,106.20, a P/E ratio of 43.43, a price-to-earnings-growth ratio of 1.60 and a beta of 0.74.

Charles River Laboratories Intl. (NYSE:CRL) last announced its quarterly earnings data on Tuesday, February 13th. The medical research company reported $1.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.26 by $0.14. Charles River Laboratories Intl. had a net margin of 6.64% and a return on equity of 26.14%. The business had revenue of $478.50 million during the quarter, compared to analyst estimates of $475.02 million. During the same period last year, the firm posted $1.21 EPS. The company’s revenue was up 2.5% on a year-over-year basis. equities research analysts anticipate that Charles River Laboratories Intl. will post 5.52 earnings per share for the current year.

In related news, Director C Richard Reese sold 10,227 shares of the firm’s stock in a transaction on Wednesday, December 6th. The stock was sold at an average price of $102.40, for a total value of $1,047,244.80. Following the completion of the sale, the director now directly owns 51,444 shares in the company, valued at $5,267,865.60. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Online Communications Bdirect sold 131,000 shares of the firm’s stock in a transaction on Thursday, January 18th. The stock was sold at an average price of $0.29, for a total value of $37,990.00. Over the last 90 days, insiders sold 195,673 shares of company stock valued at $2,644,046. 2.20% of the stock is owned by corporate insiders.

Large investors have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC lifted its position in shares of Charles River Laboratories Intl. by 1,071.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,054 shares of the medical research company’s stock worth $115,000 after purchasing an additional 964 shares during the last quarter. YorkBridge Wealth Partners LLC lifted its position in shares of Charles River Laboratories Intl. by 445.5% during the third quarter. YorkBridge Wealth Partners LLC now owns 1,091 shares of the medical research company’s stock worth $118,000 after purchasing an additional 891 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. lifted its position in shares of Charles River Laboratories Intl. by 69.0% during the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,342 shares of the medical research company’s stock worth $145,000 after purchasing an additional 548 shares during the last quarter. Advisor Group Inc. lifted its position in shares of Charles River Laboratories Intl. by 159.4% during the third quarter. Advisor Group Inc. now owns 1,538 shares of the medical research company’s stock worth $165,000 after purchasing an additional 945 shares during the last quarter. Finally, Zions Bancorporation bought a new stake in shares of Charles River Laboratories Intl. during the third quarter worth $212,000. Institutional investors and hedge funds own 97.13% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Charles River Laboratories Intl. (CRL) Rating Lowered to C+ at TheStreet” was originally reported by Markets Daily and is owned by of Markets Daily. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://www.themarketsdaily.com/2018/02/15/charles-river-laboratories-intl-crl-rating-lowered-to-c-at-thestreet.html.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Analyst Recommendations for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply